{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:46:51Z","timestamp":1787312811149,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03084-5","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T04:20:37Z","timestamp":1734409237000},"page":"995-1008","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Cost-Effectiveness Analysis of Finerenone for Treatment of Chronic Kidney Disease in Patients with Type\u00a02 Diabetes from Japanese Payer Perspective"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-6916","authenticated-orcid":false,"given":"Ataru","family":"Igarashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4513-390X","authenticated-orcid":false,"given":"Kenichi","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Morii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suchitra","family":"Jagannathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Filomeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"issue":"1","key":"3084_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/ki.2010.483","volume":"80","author":"AS Levey","year":"2011","unstructured":"Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 2011;80(1):17\u201328.","journal-title":"Kidney Int"},{"issue":"3","key":"3084_CR2","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s10157-016-1309-1","volume":"21","author":"D Inaguma","year":"2017","unstructured":"Inaguma D, Imai E, Takeuchi A, et al. Risk factors for CKD progression in Japanese patients: findings from the chronic kidney disease Japan cohort (CKD-JAC) study. Clin Exp Nephrol. 2017;21(3):446\u201356.","journal-title":"Clin Exp Nephrol"},{"issue":"10225","key":"3084_CR3","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"B Bikbov","year":"2020","unstructured":"Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"issue":"3","key":"3084_CR4","doi-asserted-by":"publisher","first-page":"e342","DOI":"10.1016\/S2214-109X(24)00050-0","volume":"12","author":"M Jadoul","year":"2024","unstructured":"Jadoul M, Aoun M, Masimango IM. The major global burden of chronic kidney disease. Lancet Glob Health. 2024;12(3):e342\u20133.","journal-title":"Lancet Glob Health"},{"issue":"10159","key":"3084_CR5","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1016\/S0140-6736(18)32335-3","volume":"392","author":"GDH Collaborators","year":"2018","unstructured":"Collaborators GDH. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990\u20132017: a systematic analysis for the global burden of disease study 2017. Lancet. 2018;392(10159):1859\u2013922.","journal-title":"Lancet"},{"key":"3084_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10157-009-0199-x","volume":"13","author":"E Imai","year":"2009","unstructured":"Imai E, Horio M, Watanabe T, et al. Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol. 2009;13:621\u201330.","journal-title":"Clin Exp Nephrol"},{"key":"3084_CR7","unstructured":"KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Public Review Draft. 2023. https:\/\/kdigo.org\/wp-content\/uploads\/2017\/02\/KDIGO-2023-CKD-Guideline-Public-Review-Draft_5-July-2023.pdf. Accessed Nov 12 2024."},{"key":"3084_CR8","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1007\/s10157-010-0328-6","volume":"14","author":"E Imai","year":"2010","unstructured":"Imai E, Matsuo S, Makino H, et al. Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function. Clin Exp Nephrol. 2010;14:558\u201370.","journal-title":"Clin Exp Nephrol"},{"issue":"6","key":"3084_CR9","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014. JAMA. 2016;316(6):602\u201310.","journal-title":"JAMA"},{"issue":"8","key":"3084_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2169\/internalmedicine.47.0906","volume":"47","author":"K Iseki","year":"2008","unstructured":"Iseki K. Chronic kidney disease in Japan. Int Med. 2008;47(8):681\u20139.","journal-title":"Int Med"},{"issue":"8","key":"3084_CR11","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1093\/ndt\/gfh317","volume":"19","author":"K Wakai","year":"2004","unstructured":"Wakai K, Nakai S, Kikuchi K, et al. Trends in incidence of end-stage renal disease in Japan, 1983\u20132000: age-adjusted and age-specific rates by gender and cause. Nephrol Dial Transplant. 2004;19(8):2044\u201352.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"3084_CR12","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1291\/hypres.31.1101","volume":"31","author":"E Imai","year":"2008","unstructured":"Imai E, Matsuo S, Makino H, et al. Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res. 2008;31(6):1101\u20137.","journal-title":"Hypertens Res"},{"issue":"4","key":"3084_CR13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/jdi.12766","volume":"9","author":"C Kusunoki-Tsuji","year":"2018","unstructured":"Kusunoki-Tsuji C, Araki SI, Kume S, et al. Impact of obesity on annual medical expenditures and diabetes care in Japanese patients with type\u00a02 diabetes mellitus. J Diabetes Investig. 2018;9(4):776\u201381.","journal-title":"J Diabetes Investig"},{"issue":"1","key":"3084_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12933-023-01928-y","volume":"22","author":"A Tanaka","year":"2023","unstructured":"Tanaka A, Shibata H, Imai T, et al. Rationale and design of an investigator-initiated, multicenter, prospective, placebo-controlled, double-blind, randomized trial to evaluate the effects of finerenone on vascular stiffness and cardiorenal biomarkers in type\u00a02 diabetes and chronic kidney disease (FIVE-STAR). Cardiovasc Diabetol. 2023;22(1):194.","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"3084_CR15","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/1744-9987.12378","volume":"19","author":"I Masakane","year":"2015","unstructured":"Masakane I, Nakai S, Ogata S, et al. An overview of regular dialysis treatment in Japan (as of 31 December 2013). Ther Apher Dial. 2015;19(6):540\u201374.","journal-title":"Ther Apher Dial"},{"issue":"3","key":"3084_CR16","doi-asserted-by":"publisher","first-page":"381","DOI":"10.7326\/M22-2904","volume":"176","author":"SD Navaneethan","year":"2023","unstructured":"Navaneethan SD, Zoungas S, Caramori ML, et al. Diabetes management in chronic kidney disease: synopsis of the KDIGO 2022 clinical practice guideline update. Annals Int Med. 2023;176(3):381\u20137.","journal-title":"Annals Int Med"},{"issue":"5S","key":"3084_CR17","first-page":"S1","volume":"102","author":"Improving Global Outcomes KDIGO Diabetes Work Group","year":"2022","unstructured":"Improving Global Outcomes KDIGO Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1\u2013127.","journal-title":"Kidney Int"},{"issue":"10","key":"3084_CR18","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/dc14-1296","volume":"37","author":"KR Tuttle","year":"2014","unstructured":"Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864\u201383.","journal-title":"Diabetes Care"},{"issue":"2 Supplement","key":"3084_CR19","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.ekir.2022.01.371","volume":"7","author":"P Rossing","year":"2022","unstructured":"Rossing P, Agarwal R, Anker SD, et al. Finerenone in mild to severe chronic kidney disease and type\u00a02 diabetes: the fidelity prespecified polled analysis. Kidney Int Rep. 2022;7(2 Supplement):S157\u20138.","journal-title":"Kidney Int Rep"},{"issue":"10166","key":"3084_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type\u00a02 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31\u20139.","journal-title":"Lancet"},{"issue":"5","key":"3084_CR21","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000503713","volume":"50","author":"GL Bakris","year":"2019","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):333\u201344.","journal-title":"Am J Nephrol"},{"issue":"5","key":"3084_CR22","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000503712","volume":"50","author":"LM Ruilope","year":"2019","unstructured":"Ruilope LM, Agarwal R, Anker SD, et al. Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial. Am J Nephrol. 2019;50(5):345\u201356.","journal-title":"Am J Nephrol"},{"key":"3084_CR23","unstructured":"Bayer. Bayer receives approval in Japan for Kerendia\u2122 (finerenone), a new treatment for adults with chronic kidney disease and type 2 diabetes 2022 [updated 28 March 2022]. https:\/\/www.bayer.com\/media\/en-us\/bayer-receives-approval-in-japan-for-kerendiatm-finerenone-a-new-treatment-for-adults-with-chronic-kidney-disease-and-type-2-diabetes\/."},{"issue":"6","key":"3084_CR24","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type\u00a02 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474\u201384.","journal-title":"Eur Heart J"},{"issue":"6","key":"3084_CR25","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/hr.2009.51","volume":"32","author":"A Higashiyama","year":"2009","unstructured":"Higashiyama A, Okamura T, Watanabe M, et al. Effect of chronic kidney disease on individual and population medical expenditures in the Japanese population. Hypertens Res. 2009;32(6):450\u20134.","journal-title":"Hypertens Res"},{"issue":"5","key":"3084_CR26","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1097\/01.ASN.0000125670.64996.BB","volume":"15","author":"DH Smith","year":"2004","unstructured":"Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care for chronic kidney disease and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol. 2004;15(5):1300\u20136.","journal-title":"J Am Soc Nephrol"},{"key":"3084_CR27","unstructured":"Center for Outcomes Research and Economic Evaluation for Health- National Institute of Public Health (C2H Japan). Guideline for preparing cost-effectiveness evaluation to the Central Social Insurance Medical Council. Version 3 2022 [updated 19-Jan-2022]. https:\/\/c2h.niph.go.jp\/tools\/guideline\/guideline_en.pdf. Accessed Nov 12 2024."},{"key":"3084_CR28","unstructured":"Chuikyo. [Cost-effectiveness evaluation of pharmaceuticals and other products] 2021. https:\/\/www.mhlw.go.jp\/content\/12404000\/000855564.pdf. Accessed Nov 12 2024."},{"issue":"8","key":"3084_CR29","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jval.2021.03.010","volume":"24","author":"T Shiroiwa","year":"2021","unstructured":"Shiroiwa T, Noto S, Fukuda T. Japanese population norms of EQ-5D-5L and health utilities index mark 3: disutility catalog by disease and symptom in community settings. Value Health. 2021;24(8):1193\u2013202.","journal-title":"Value Health"},{"key":"3084_CR30","unstructured":"MDV. MDV Database Overview Tokyo: MDV. https:\/\/en.mdv.co.jp\/about-mdv-database\/mdv-database-overview\/. Accessed Nov 12 2024."},{"key":"3084_CR31","unstructured":"Ministry of Health LaWM. National fee schedule 2022. https:\/\/shinryohoshu.mhlw.go.jp\/shinryohoshu\/kaitei\/doKaiteiR04\/. Accessed Nov 12 2024."},{"issue":"23","key":"3084_CR32","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type\u00a02 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"1","key":"3084_CR33","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12933-023-02053-6","volume":"22","author":"SW Quist","year":"2023","unstructured":"Quist SW, van Schoonhoven AV, Bakker SJL, et al. Cost-effectiveness of finerenone in chronic kidney disease associated with type\u00a02 diabetes in the Netherlands. Cardiovasc Diabetol. 2023;22(1):328\u201344.","journal-title":"Cardiovasc Diabetol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03084-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03084-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:52:08Z","timestamp":1738389128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03084-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,17]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3084"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03084-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,17]]},"assertion":[{"value":"24 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ataru Igarashi received consulting fees from Bayer. Kenichi Ohara is an employee of Bayer. Hiroyuki Matsuda, Junko Morii, Suchitra Jagannathan, and Ronald Filomeno are employees of IQVIA.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study is based on data from previously conducted studies and does not include any new human participants or patients enrolled in this study. Therefore, this study complies with ethical guidelines and did not require an ethics review and approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}